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DOI 10.1186/s13054-014-0712-9RESEARCH Open AccessHigh-flow nasal cannula oxygen versus
non-invasive ventilation in patients with acute
hypoxaemic respiratory failure undergoing
flexible bronchoscopy - a prospective
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Introduction: Critically ill patients with respiratory failure undergoing bronchoscopy have an increased risk of
hypoxaemia-related complications. Previous studies have shown that in awake, hypoxaemic patients non-invasive
ventilation (NIV) is helpful in preventing gas exchange deterioration during bronchoscopy. An alternative and
increasingly used means of oxygen delivery is its application via high-flow nasal cannula (HFNC). This study was
conducted to compare HFNC with NIV in patients with acute hypoxaemic respiratory failure undergoing flexible
bronchoscopy.
Methods: Prospective randomised trial randomising 40 critically ill patients with hypoxaemic respiratory failure to
receive either NIV or HFNC during bronchoscopy in the intensive care unit.
Results: After the initiation of NIV and HFNC, oxygen levels were significantly higher in the NIV group compared to
the HFNC group. Two patients were unable to proceed to bronchoscopy after the institution of HFNC due to
progressive hypoxaemia. During bronchoscopy, one patient on HFNC deteriorated due to intravenous sedation
requiring non-invasive ventilatory support. Bronchoscopy was well tolerated in all other patients. There were no
significant differences between the two groups regarding heart rate, mean arterial pressure and respiratory rate.
Three patients in the NIV group and one patient in the HFNC group were intubated within 24 hours after the end
of bronchoscopy (P = 0.29).
Conclusions: The application of NIV was superior to HFNC with regard to oxygenation before, during and after
bronchoscopy in patients with moderate to severe hypoxaemia. In patients with stable oxygenation under HFNC,
subsequent bronchoscopy was well tolerated.
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1Department of Intensive Care Medicine, University Medical Centre
Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
Full list of author information is available at the end of the article
© 2014 Simon et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Simon et al. Critical Care  (2014) 18:712 Page 2 of 9Introduction
Flexible bronchoscopy (FB) is a frequently performed
procedure for the assessment, diagnosis, and treatment
of patients with respiratory disease in the intensive care
unit (ICU). The procedure and applications of FB have
progressively evolved and expanded since it was first in-
troduced in 1968 and it is now well established as an in-
tegral diagnostic and therapeutic tool in respiratory and
critical care medicine [1,2].
While bronchoscopy is generally considered a safe
procedure [3], it is well known that critically ill pa-
tients undergoing bronchoscopy are at an increased
risk for complications, most of all the deterioration of
pre-existing hypoxaemia [4].
Few randomised controlled studies and case series have
shown that the use of continuous positive airway pressure
(CPAP) or non-invasive ventilation (NIV) is superior to
conventional means of oxygen delivery in patients with
hypoxaemia in terms of preventing deterioration of gas
exchange during bronchoscopy [5-12].
High-flow nasal cannula (HFNC) oxygen utilises higher
gas flow rates than conventional low-flow oxygen systems.
Oxygenation via HFNC is increasingly applied in adult
ICU patients with acute hypoxaemic respiratory failure as
an alternative to NIV [13]. The devices used deliver heated
and humidified oxygen at a flow of up to 60 litres per
minute via nasal cannulas. This results in effective and
sustained improvement in respiratory parameters in pa-
tients with acute hypoxaemic respiratory failure by several
mechanisms [14].
In a pilot study, Lucangelo et al. found that HFNC im-
proves oxygenation in patients undergoing bronchos-
copy [15]. However, the patients investigated were not
hypoxaemic and there was no comparison with NIV.
Therefore, we conducted this prospective randomised
trial comparing HFNC with NIV in patients with acute
hypoxaemic respiratory failure undergoing FB to assess
the ability to maintain oxygen saturation during bron-
choscopy as well as changes in blood gases and outcome
following bronchoscopy.Methods
Study design
The study was conducted as a prospective randomised
trial. All patients admitted to the Department of Intensive
Care Medicine at the University Medical Centre Hamburg-
Eppendorf were eligible for study inclusion. Prior to enrol-
ment, all participants or their legal representatives gave
written informed consent. The study was approved by the
ethics committee of the chamber of physicians in Hamburg,
Germany, and the trial was registered at ClinicalTrials.gov
(registration number NCT01870765, registration date 30
May 2013).Study population
Medical and surgical patients treated in one of the ten
departmental ICUs were enrolled. Inclusion criteria were
(1) respiratory failure with hypoxaemia defined as partial
pressure of oxygen in arterial blood/fraction of inspired
oxygen (PaO2/FiO2) below 300 mm Hg, (2) indication
for diagnostic and/or therapeutic FB, (3) age 18 years or
above and (4) informed consent. Exclusion criteria were
(1) contraindications for NIV or HFNC, (2) nasopharyn-
geal obstruction or blockage, (3) indication for intub-
ation and (4) pre-existing invasive ventilation.
Simplified acute physiology scores II (SAPS II) were
calculated according to standard criteria [16]. Immuno-
suppression was defined as a neutrophil count of less
than 1,000/mL, immunosuppressive medication, chemo-
therapy within the last 60 days or acquired immunodefi-
ciency syndrome.
Study protocol
After enrolment, patients were randomised to receive
either NIV or HFNC. Randomisation was accomplished
by computer-generated random number sequence and the
allocation sequence was concealed from the study team
enrolling and assessing participants by using numbered,
opaque and sealed envelopes.
Arterial blood gases were drawn from a catheter in the
radial or femoral artery at baseline, 15 minutes after the
institution of NIV or HFNC, after 5 minutes on FiO2 1.0
just before the start of bronchoscopy, at the end of bron-
choscopy as well as 10, 20, 30, 40 and 50 minutes after the
completion of bronchoscopy. Blood pressure, heart rate,
respiratory rate and oxygen saturation recorded by pulse
oximetry (SpO2) were monitored constantly throughout
this period. For details on study workflow see the flow dia-
gram in Figure 1.
Non-invasive ventilation (NIV)
NIV was administered using ICU ventilators in NIV mode
(Carina™ or Evita Infinity V500™, Dräger, Germany). A full
face mask (Medisize, Neunkirchen-Seelscheid, Germany)
secured with elastic banding was used as the interface.
A swivel connector was inserted between the mask and
ventilator tubing to allow for the insertion of the bron-
choscope. The ventilator mode was set to pressure support
mode or pressure controlled mode. Positive end-expiratory
pressure (PEEP) was set between 3 and 10 cm H2O and
inspiratory pressures between 15 and 20 cm H2O to
achieve adequate oxygenation and ventilation. The adjust-
ment of ventilator settings was left to the discretion of the
treating intensivist.
High-flow nasal cannula (HFNC) oxygen
To deliver high-flow oxygen, an Optiflow™ system with a
medium-size adult nasal cannula as patient interface
Figure 1 Study workflow. Abbreviations: ABG, arterial blood gas analysis; FiO2, fraction of inspired oxygen; HFNC, high-flow nasal cannula; NIV,
non-invasive ventilation.
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was used in all cases. The oxygen flow was set to 50 litres
per minute.
Flexible bronchoscopy (FB)
All bronchoscopies were performed by experienced pul-
monologists. The decision to perform bronchoscopy was
not part of the study and was left to the discretion of the
treating intensivist. The FiO2 was increased to 1.0 prior
to the start of bronchoscopy and adjusted to maintain
an arterial oxygen saturation of more than 90% after the
completion of bronchoscopy. A flexible bronchoscope
(BF-P60™, Olympus, Tokyo, Japan) passed through the
mouth was used for all procedures. The setup using NIV
or HFNC is illustrated in Figure 2. Intravenous sedation
was achieved in a standardised manner using repetitive
bolus applications of 10 to 20 mg of propofol every 2 to
3 minutes. Topical anaesthesia was applied to the nasal
and pharyngeal mucosa using lidocain gel and spray and
to the tracheobronchial mucosa using 5 mL of lidocain
0.8% applied through the working channel of the bron-
choscope in aliquots of 1 mL. After inspection of the
tracheobronchial tree, the bronchoscope was wedged in
the appropriate subsegmental bronchus. Bronchoalveolar
lavage (BAL) was performed using normal saline being
instilled in aliquots of 20 mL and then aspirated. The
number and type of diagnostic tests ordered determinedthe amount of fluid required. Depending on the under-
lying condition, BAL fluid was sent for cytological or
microbiological analyses. The duration of bronchoscopy
was defined as the time between insertion and removal
of the bronchoscope from the tracheobronchial tree.
Outcome parameters
Primary outcome parameter was the lowest oxygen satur-
ation recorded by pulse oximetry during FB. Secondary
outcome parameters were (1) changes in blood gases for
up to 50 minutes after the procedure and (2) the require-
ment for intubation within 8 hours of completion of FB
and at any other point during ICU stay. Intubation was
considered a complication possibly related to bronchos-
copy, if it occurred within 8 hours of the procedure. This
time frame was adopted from previous studies [7,17,18].
The decision to intubate was left to the discretion of
the treating intensivist in accordance with published
guidelines [19]. Sample size was calculated to allow the
detection of a 3% difference in minimal oxygen satur-
ation during FB assuming an alpha risk of 0.05 and a
power of 0.8.
Statistical analysis
Results are presented as absolute numbers and percent-
ages, as mean and standard deviation for continuous
data if normally distributed and as median and range if
Figure 2 Illustration of bronchoscopy using HFNC (A) or NIV (B). HFNC, high-flow nasal cannula; NIV, non-invasive ventilation.
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groups was performed using the t test or the Mann-
Whitney U test for metric data and the chi-square test
for categorical data. A two-sided P value of less than
0.05 was considered to be significant. The software
used for descriptive analyses was SPSS (version 20.0,
SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Between July 2013 and December 2013, 44 patients met
inclusion criteria and were found eligible to participate
in the study. Of these, two patients declined informed
consent. Two patients who were randomised to receive
HFNC were unable to proceed to bronchoscopy after
the institution of HFNC due to progressive hypoxaemia
requiring the initiation of NIV: one patient who had pre-
viously been breathing spontaneously on HFNC deterio-
rated due to the retention of secretions, the other
patient who had been on NIV deteriorated when trans-
ferred to HFNC. Eventually, 40 patients were enrolled in
the study and were randomised to undergo FB while on
HFNC or on NIV.
Mean PaO2/FiO2 at baseline was 138 ± 69 mm Hg in
the HFNC group and 163 ± 64 mm Hg in the NIV group
(P = 0.25). Mean partial pressure of carbon dioxide in ar-
terial blood (PaCO2) levels at baseline were significantly
higher in the NIV group (43 ± 13 mm Hg) than in the
HFNC group (34 ± 6 mm Hg) (P = 0.01). Table 1 provides
further details on patient characteristics.Tolerance of the procedure
The lowest SpO2 during bronchoscopy was 95 ± 5% in the
NIV group and 92 ± 7% in the HFNC group (P = 0.07). At
the pre-defined time points during the 50 minutes of
follow-up as well as at 24 hours after the completion of
bronchoscopy, no SpO2 of less than 85% was registered in
any of the two groups. SpO2 values before and after bron-
choscopy are shown in Figure 3.
A significant increase in PaO2/FiO2 after 15 minutes
on NIV compared to baseline (P = 0.04) was observed in
the NIV group, while there was no significant change in
PaO2/FiO2 in the HFNC group (P = 0.96). Comparing
the two groups after 15 minutes on NIV or HFNC,
PaO2/FiO2 was significantly better in the NIV group
(P = 0.002). This difference in oxygenation was preserved
throughout bronchoscopy and during the 50 minutes of
follow-up. There were no significant differences between
the two groups concerning respiratory rates and the
course of PaCO2 values. At 24 hours after the completion
of bronchoscopy, there was no significant difference be-
tween the two groups concerning PaO2/FiO2 (P = 0.29) or
any of the other recorded parameters. Figure 4 shows
PaO2/FiO2 and PaCO2 before and after bronchoscopy.
One patient in the HFNC group deteriorated after the
application of intravenous sedation resulting in apnea
while on HFNC requiring transitioning to NIV. Subse-
quent bronchoscopy was completed without further inci-
dent. Bronchoscopy was well tolerated by all other
patients. The average duration of bronchoscopy was 5.0 ±
2.7 minutes in the HFNC group and 5.5 ± 1.9 minutes
Table 1 Patient characteristics
NIV HFNC P value
Total number of patients 20 20
Gender
Male 13 (65%) 11 (55%) 0.52
Female 7 (35%) 9 (45%)
Age (years) 68 ± 11 64 ± 12 0.28
SAPS II score 46 ± 10 43 ± 13 0.39
Thrombocytopenia (<50 Mrd/L) 3 (15%) 5 (25%) 0.43
Immunosuppression 8 (40%) 5 (25%) 0.31
Use of vasopressors 10 (50%) 10 (50%) 1.00
Antibiotic therapy 17 (85%) 19 (95%) 0.29
Antimycotic therapy 5 (25%) 6 (30%) 0.72
Antiviral therapy 3 (15%) 7 (35%) 0.14
Main diagnosis
Haematological disorder 4 (20%) 7 (35%) 0.29
Sepsis 4 (20%) 3 (15%) 0.68
Lung cancer 2 (10%) 3 (15%) 0.63
Extrapulmonary solid cancer 2 (10%) 3 (15%) 0.63
Liver cirrhosis 1 (5%) 1 (5%) 1.00
Trauma 1 (5%) 1 (5%) 1.00
Interstitial lung disease 1 (5%) 1 (5%) 1.00
Alveolar haemorrhage 1 (5%) 0 0.31
Community-acquired pneumonia 1 (5%) 0 0.31
Chronic obstructive pulmonary
disease
1 (5%) 0 0.31
Pulmonary arterial hypertension 1 (5%) 0 0.31
Acquired immunodeficiency
syndrome
0 1 (5%) 0.31
Ileum perforation 1 (5%) 0 0.31
Indication for bronchoscopy
Hospital-acquired pneumonia 10 (50%) 14 (70%) 0.50
Community-acquired pneumonia 5 (25%) 3 (15%)
Suspected retention of secretions 3 (15%) 2 (10%)
Suspected interstitial lung disease 1 (5%) 0
Suspected alveolar haemorrhage 1 (5%) 0
Suspected malignancy 0 1 (5%)
Therapy at baseline
Low-flow oxygen via nasal cannula 5 (25%) 2 (10%) 0.23
Low-flow oxygen via face mask 1 (5%) 3 (15%)
HFNC 9 (45%) 13 (65%)
NIV 5 (25%) 2 (10%)
Table 1 Patient characteristics (Continued)
Physiological parameters at baseline
Heart rate (beats/min) 95 ± 14 101 ± 15 0.27
Mean arterial pressure (mm Hg) 85 ± 11 82 ± 14 0.56
Respiratory rate (breaths/min) 30 ± 8 30 ± 9 0.86
PaO2/FiO2 (mm Hg) 163 ± 64 138 ± 69 0.25
PaCO2 (mm Hg) 43 ± 13 34 ± 6 0.01
pH 7.43 ± 0.11 7.46 ± 0.07 0.21
Values are given as mean and standard deviation or as numbers and
percentages. FiO2, fraction of inspired oxygen; HFNC, high-flow nasal cannula;
NIV, non-invasive ventilation; PaCO2, partial pressure of carbon dioxide in arterial
blood; PaO2, partial pressure of oxygen in arterial blood; SAPS II, simplified acute
physiology score II.
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amount of propofol used for sedation, there was no sig-
nificant difference between the NIV group (74 ± 36 mg)
and the HFNC group (96 ± 59 mg) (P = 0.24). A BAL
was performed in all cases. The amount of BAL fluid in-
stilled was not significantly different between the two
groups (P = 0.92).
There were no significant differences between the two
groups at any of the pre-specified time points with re-
gard to heart rate and mean arterial pressure.
Patients who were on low-flow oxygen therapy at
baseline and were randomised to undergo bronchoscopy
under NIV, stayed on NIV for a median duration of 20
minutes (range 0 to 9 hours) after the end of bronchos-
copy, while patients who were randomised to undergo
bronchoscopy under HFNC, stayed on HFNC for a me-
dian duration of 7.8 hours (range 1.5 to 103 hours) after
the end of bronchoscopy (P = 0.04).
Outcome
One patient in the HFNC group required intubation im-
mediately after the completion of bronchoscopy. He had
exhibited the lowest PaO2/FiO2 value (64 mm Hg) of all
patients at baseline. None of the other patients in the
two groups required intubation within the pre-defined
period of 8 hours after the end of bronchoscopy (P = 0.31).
During the following course of their ICU stay, 13 pa-
tients (65%) in the NIV group and 9 patients (45%) in
the HFNC group required intubation (P = 0.20). Overall,
3 patients in the NIV group and 1 patient in the HFNC
group were intubated within 24 hours after the end of
bronchoscopy (P = 0.29). On average, intubation was
performed 59 hours (range 9 to 391 hours) after the
completion of bronchoscopy in the NIV group and 75
hours (range 0 to 338 hours) in the HFNC group (P =
0.54). In all these cases, intubation was due to progres-
sion of the underlying disease and not a consequence of
the bronchoscopic procedure. Twenty-eight-day mortal-
ity was 40% in the NIV group and 65% in the HFNC
group (P = 0.11).
Figure 3 SpO2 at baseline, pre and post bronchoscopy. Changes in SpO2. Values are given as mean and standard deviation. HFNC, high-flow
nasal cannula; NIV, non-invasive ventilation; SpO2, oxygen saturation recorded by pulse oximetry.
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In this randomised study, NIV was superior to HFNC
with regard to maintaining adequate oxygenation before,
during and after bronchoscopy in patients with acute
hypoxaemic respiratory failure. In two patients transition
to HFNC was impossible due to progressive hypoxaemia.
FB was well tolerated and was not associated with
complications.
To our knowledge, this is the first study comparing
HFNC with NIV in hypoxaemic patients undergoing FB.
Only two previous reports have assessed the use of
HFNC for bronchoscopy. Lucangelo et al. compared
three groups of patients with mild hypoxaemia undergo-
ing bronchoscopy while being on different types of oxy-
gen supplementation [15]. At the end of bronchoscopy,
oxygenation was significantly better in patients receiving
HFNC with a high flow rate of 60 litres per minute com-
pared with HFNC with a lower flow rate of 40 litres per
minute or oxygen administration through a Venturi mask.
Lomas et al. reported the case of a patient with myasthe-
nia gravis and severe acute respiratory failure due to bilat-
eral atelectasis who underwent successful bronchoscopy
using HFNC [20].
The concept of high-flow oxygen originates from the
treatment of premature infants as an alternative to nasal
CPAP [21,22]. Due to the ease of application, simplicity
and good patient tolerance, HFNC is increasingly used
in adult patients with acute hypoxaemic respiratory fail-
ure as an alternative to NIV [13]. It has also been shown
that HFNC is better tolerated and more comfortable
than oxygen applied via face mask [23]. In addition, the
use of this technique has been described as means for
pre-oxygenation before intubation [24], in the post-extubation period [25], in patients with do-not-intubate
order [26], in the palliative care setting [27], in the emer-
gency department [28] and in patients with heart failure
[29]. Most of these observational studies showed benefi-
cial effects of HFNC compared with conventional oxy-
gen therapy in terms of improved symptoms (dyspnea
score), respiratory rate and oxygenation. In one of the
few randomised studies, the authors compared HFNC
with standard low-flow oxygen therapy in patients with
mild to moderate hypoxaemic respiratory failure. Signifi-
cantly more HFNC patients succeeded with their allocated
therapy and also had significantly fewer desaturations
[30]. However, in relation to its widespread use, there is
still little evidence concerning the risks and benefits of
this new technology. Moreover, most studies are lacking
clinical outcome data and assessment of long-term
effects [31].
A number of physiological effects of HFNC have been
described. These include the washout of pharyngeal dead
space, reduction of airway resistance, increase in end-
expiratory lung volume and generation of positive airway
pressure [13,14,31]. In our study, after the initiation of
NIV or HFNC, oxygenation was significantly better in the
NIV group than in the HFNC group (P = 0.002). This can,
at least in part, be explained by higher positive airway
pressures generated by NIV [32]. Positive airway pressures
with HFNC have been documented. In line with other re-
searchers, Parke et al. found a positive linear relationship
between oxygen flow and airway pressure. In the study on
ICU patients, a significant difference in the degree of posi-
tive airway pressure was seen dependent on whether the
person’s mouth was open or closed: a mean positive air-
way pressure of 2.7 cm H2O was reported with the mouth
Figure 4 PaO2/FiO2 and PaCO2 at baseline, pre and post bronchoscopy. Changes in PaO2/FiO2 (A) and PaCO2 (B). Values are given as mean
and standard deviation. *P <0.05; n.s. not significant. FiO2, fraction of inspired oxygen; HFNC, high-flow nasal cannula; NIV, non-invasive ventilation;
PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial pressure of oxygen in arterial blood.
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[33]. Accordingly, in a study on healthy volunteers, a me-
dian positive airway pressure of 7.4 cm H2O was observed
with the mouth closed, while it was 2.7 cm H2O with the
mouth open [34]. Patients with more severe acute respira-
tory distress may have more inconsistent airway pressures
due to their breathing through an open mouth. A funda-
mental difference between HFNC and NIV is the fact that
HFNC systems maintain a fixed flow and generate variable
pressures, whereas many NIV systems generate a fixed
pressure by utilising variable flow [13]. In contrast to the
NIV group, where the average PEEP was 5.4 cm H2O, it
can be assumed that no relevant PEEP levels were achieved
in the HFNC group due to the procedure-related openmouth. This is most likely the main reason for the differ-
ences observed in oxygenation between the two groups.
In addition to hypoxaemia, bronchoscopy can be asso-
ciated with hypercapnia and side effects of sedation. This
happened in one case in our study where the need for
NIV was due to intravenous sedation. A recent multi-
centre study investigating 169 bronchoscopies in spon-
taneously breathing hypoxaemic patients showed that
one-third of cases were complicated by an increased
need for ventilatory support [12]. Thus, in patients with
ventilatory failure (primary ventilatory pump failure or
secondary due to sedation) support or maintenance of
ventilation by NIV seems advantageous in comparison to
HFNC.
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considered: first, despite randomisation baseline PaCO2
levels were higher in the NIV group. However, subse-
quent changes in PaCO2 over time were similar in both
groups. Second, our results are only applicable to popu-
lations with similar characteristics. It is therefore import-
ant to note that most critically ill patients in this study
had moderate to severe hypoxaemic respiratory failure,
high SAPS II values and vasopressor support.
Although oxygenation levels were lower in the HFNC
group, all patients who were stable on HFNC for 15
minutes tolerated subsequent bronchoscopy well. A signifi-
cant difference concerning the need for intubation between
the two groups could not be detected. However, this study
was not powered to answer this question and further stud-
ies including more patients are needed to assess this topic.
Thus, patients stable on HFNC may undergo bronchoscopy
without the need for transitioning to NIV. This may facili-
tate the procedure for ICU staff and provide improved pa-
tient comfort due to the avoidance of the potentially
unpleasant experience of NIV. The fact that patients on
low-flow oxygen therapy at baseline remained on HFNC
significantly longer than on NIV after the end of bronchos-
copy, may be due to improved patient comfort under
HFNC. However, this study was not designed to assess this
question. Since no benefits for HFNC over NIV for bron-
choscopy in hypoxaemic patients have been shown so far
and HFNC therapy is, at least in our setting, associated with
higher costs for disposables compared with NIV, assessment
of patient comfort should also be a key element in further
studies. Considering the improved oxygenation capacity of
NIV in comparison with HFNC, we believe that patients with
severe hypoxaemia should preferably undergo bronchoscopy
using NIV. Intubation prior to bronchoscopy should be
considered in patients with most severe hypoxaemia.
Conclusions
In conclusion, the results of this study suggest, that in
awake, critically ill patients with moderate to severe
hypoxaemia undergoing bronchoscopy, the application
of NIV was superior to HFNC regarding oxygenation
before, during and after the procedure. However, in
patients who were stable on HFNC, bronchoscopy
was well tolerated using HFNC.
Key messages
 Non-invasive ventilation (NIV) was superior to
high-flow nasal cannula (HFNC) oxygen with
regard to oxygenation before, during and after
bronchoscopy in patients with moderate to severe
hypoxaemia.
 In patients with stable oxygenation under HFNC,
bronchoscopy was well tolerated under HFNC.Abbreviations
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